Boston Scientific Corporation logo

Boston Scientific Corporation (BSX)

Market Closed
16 Dec, 21:00
NYSE NYSE
$
92. 95
+0.76
+0.82%
$
149.67B Market Cap
74.55 P/E Ratio
0% Div Yield
11,869,813 Volume
2.01 Eps
$ 92.19
Previous Close
Day Range
90.42 93.17
Year Range
85.98 109.5
Want to track BSX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 50 days
Here's Why Boston Scientific (BSX) is a Strong Growth Stock

Here's Why Boston Scientific (BSX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 7 hours ago
4 Medical Device Stocks to Buy for Healthy Returns in 2026

4 Medical Device Stocks to Buy for Healthy Returns in 2026

ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.

Zacks | 1 day ago
Boston Scientific (BSX) Stock Falls Amid Market Uptick: What Investors Need to Know

Boston Scientific (BSX) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Boston Scientific (BSX) settling at $91.75, representing a -1.02% change from its previous close.

Zacks | 4 days ago
Boston Scientific Sustains Momentum in the PFA Market: What's Next?

Boston Scientific Sustains Momentum in the PFA Market: What's Next?

BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.

Zacks | 5 days ago
Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript

Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript

Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript

Seekingalpha | 2 weeks ago
M&A Strategy Strengthens Boston Scientific's Growth Prospects

M&A Strategy Strengthens Boston Scientific's Growth Prospects

BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.

Zacks | 2 weeks ago
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term

Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 2 weeks ago
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 2 weeks ago
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 3 weeks ago
Boston Scientific's Margins Strengthen in Q3: What's Driving It?

Boston Scientific's Margins Strengthen in Q3: What's Driving It?

BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Zacks | 3 weeks ago
BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?

BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?

Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Zacks | 3 weeks ago
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know

Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 3 weeks ago
Loading...
Load More